Cargando…
Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor
Cervical cancer is one of the most common cancers in women. The development of new therapies with immune checkpoint inhibitors (ICIs) is being investigated for cervical cancer; however, their efficacy is not currently sufficient. Oncolytic virus therapy can increase tumor immunogenicity and enhance...
Autores principales: | Kagabu, Masahiro, Yoshino, Naoto, Murakami, Kazuyuki, Kawamura, Hideki, Sasaki, Yutaka, Muraki, Yasushi, Baba, Tsukasa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916424/ https://www.ncbi.nlm.nih.gov/pubmed/36768352 http://dx.doi.org/10.3390/ijms24031988 |
Ejemplares similares
-
Third‐generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice
por: Nakatake, Richi, et al.
Publicado: (2018) -
Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions
por: Kagabu, Masahiro, et al.
Publicado: (2020) -
Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018) -
Mast cells partially contribute to mucosal adjuvanticity of surfactin in mice
por: Yoshino, Naoto, et al.
Publicado: (2017) -
Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)